Idiopathic pulmonary fibrosis (IPF) is a progressivediseasewithamediansurvivalof 3–5 years (1, 2). The approval of nintedanib and pirfenidone by regulatory agencies worldwide has dramatically altered the landscape for testing new drugs for IPF treatment. These drugs slowed the progression of the FVC decline observed in IPF cohorts in phase III randomized, double-blind, placebo-controlled trials (3, 4).

Kaner, R. J., Bajwa, E. K., El-Amine, M., Gorina, E., Gupta, R., Lazarus, H. M., Luckhardt, T. R., Mouded, M., Posada, K., Richeldi, L., Stauffer, J., Tutuncu, A., Martinez, F. J., Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies, <<AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE>>, 2019; 200 (2): 133-139. [doi:10.1164/rccm.201903-0592PP] [http://hdl.handle.net/10807/147464]

Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies

Richeldi, L.;
2019

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressivediseasewithamediansurvivalof 3–5 years (1, 2). The approval of nintedanib and pirfenidone by regulatory agencies worldwide has dramatically altered the landscape for testing new drugs for IPF treatment. These drugs slowed the progression of the FVC decline observed in IPF cohorts in phase III randomized, double-blind, placebo-controlled trials (3, 4).
Inglese
Kaner, R. J., Bajwa, E. K., El-Amine, M., Gorina, E., Gupta, R., Lazarus, H. M., Luckhardt, T. R., Mouded, M., Posada, K., Richeldi, L., Stauffer, J., Tutuncu, A., Martinez, F. J., Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies, <<AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE>>, 2019; 200 (2): 133-139. [doi:10.1164/rccm.201903-0592PP] [http://hdl.handle.net/10807/147464]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/147464
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 6
social impact